A: | SECTION A HUMAN NECESSITIES | |
A61: | MEDICAL OR VETERINARY SCIENCE; HYGIENE | |
A61P: | SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | |
A61P1/00: | Drugs for disorders of the alimentary tract or the digestive system | |
A61P1/02: | . Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis | |
A61P1/04: | . for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants | |
A61P1/06: | . Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia | |
A61P1/08: | . for nausea, cinetosis or vertigo; Antiemetics | |
A61P1/10: | . Laxatives | |
A61P1/12: | . Antidiarrhoeals | |
A61P1/14: | . Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents | |
A61P1/16: | . for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics | |
A61P1/18: | . for pancreatic disorders, e.g. pancreatic enzymes | |
A61P3/00: | Drugs for disorders of the metabolism | |
A61P3/02: | . Nutrients, e.g. vitamins, minerals | |
A61P3/04: | . Anorexiants; Antiobesity agents | |
A61P3/06: | . Antihyperlipidemics | |
A61P3/08: | . for glucose homeostasis | |
A61P3/10: | . . for hyperglycaemia, e.g. antidiabetics | |
A61P3/12: | . for electrolyte homeostasis | |
A61P3/14: | . . for calcium homeostasis | |
A61P5/00: | Drugs for disorders of the endocrine system | |
A61P5/02: | . of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin | |
A61P5/04: | . . for decreasing, blocking or antagonising the activity of the hypothalamic hormones | |
A61P5/06: | . of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH | |
A61P5/08: | . . for decreasing, blocking or antagonising the activity of the anterior pituitary hormones | |
A61P5/10: | . of the posterior pituitary hormones, e.g. oxytocin, ADH | |
A61P5/12: | . . for decreasing, blocking or antagonising the activity of the posterior pituitary hormones | |
A61P5/14: | . of the thyroid hormones, e.g. T3, T4 | |
A61P5/16: | . . for decreasing, blocking or antagonising the activity of the thyroid hormones | |
A61P5/18: | . of the parathyroid hormones | |
A61P5/20: | . . for decreasing, blocking or antagonising the activity of PTH | |
A61P5/22: | . . for decreasing, blocking or antagonising the activity of calcitonin | |
A61P5/24: | . of the sex hormones | |
A61P5/26: | . . Androgens | |
A61P5/28: | . . Antiandrogens | |
A61P5/30: | . . Oestrogens | |
A61P5/32: | . . Antioestrogens | |
A61P5/34: | . . Gestagens | |
A61P5/36: | . . Antigestagens | |
A61P5/38: | . of the suprarenal hormones | |
A61P5/40: | . . Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids | |
A61P5/42: | . . for decreasing, blocking or antagonising the activity of mineralocorticosteroids | |
A61P5/44: | . . Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids | |
A61P5/46: | . . for decreasing, blocking or antagonising the activity of glucocorticosteroids | |
A61P5/48: | . of the pancreatic hormones | |
A61P5/50: | . . for increasing or potentiating the activity of insulin | |
A61P7/00: | Drugs for disorders of the blood or the extracellular fluid | |
A61P7/02: | . Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors | |
A61P7/04: | . Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents | |
A61P7/06: | . Antianaemics | |
A61P7/08: | . Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock | |
A61P7/10: | . Antioedematous agents; Diuretics | |
A61P7/12: | . Antidiuretics, e.g. drugs for diabetes insipidus | |
A61P9/00: | Drugs for disorders of the cardiovascular system | |
A61P9/02: | . Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives | |
A61P9/04: | . Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure | |
A61P9/06: | . Antiarrhythmics | |
A61P9/08: | . Vasodilators for multiple indications | |
A61P9/10: | . for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis | |
A61P9/12: | . Antihypertensives | |
A61P9/14: | . Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers | |
A61P11/00: | Drugs for disorders of the respiratory system | |
A61P11/02: | . Nasal agents, e.g. decongestants | |
A61P11/04: | . for throat disorders | |
A61P11/06: | . Antiasthmatics | |
A61P11/08: | . Bronchodilators | |
A61P11/10: | . Expectorants | |
A61P11/12: | . Mucolytics | |
A61P11/14: | . Antitussive agents | |
A61P11/16: | . Central respiratory analeptics | |
A61P13/00: | Drugs for disorders of the urinary system | |
A61P13/02: | . of urine or of the urinary tract, e.g. urine acidifiers | |
A61P13/04: | . for urolithiasis | |
A61P13/06: | . Anti-spasmodics | |
A61P13/08: | . of the prostate | |
A61P13/10: | . of the bladder | |
A61P13/12: | . of the kidneys | |
A61P15/00: | Drugs for genital or sexual disorders; Contraceptives | |
A61P15/02: | . for disorders of the vagina | |
A61P15/04: | . for inducing labour or abortion; Uterotonics | |
A61P15/06: | . Antiabortive agents; Labour repressants | |
A61P15/08: | . for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis | |
A61P15/10: | . for impotence | |
A61P15/12: | . for climacteric disorders | |
A61P15/14: | . for lactation disorders, e.g. galactorrhoea | |
A61P15/16: | . Masculine contraceptives | |
A61P15/18: | . Feminine contraceptives | |
A61P17/00: | Drugs for dermatological disorders | |
A61P17/02: | . for treating wounds, ulcers, burns, scars, keloids, or the like | |
A61P17/04: | . Antipruritics | |
A61P17/06: | . Antipsoriatics | |
A61P17/08: | . Antiseborrheics | |
A61P17/10: | . Anti-acne agents | |
A61P17/12: | . Keratolytics, e.g. wart or anti-corn preparations | |
A61P17/14: | . for baldness or alopecia | |
A61P17/16: | . Emollients or protectives, e.g. against radiation | |
A61P17/18: | . Antioxidants, e.g. antiradicals | |
A61P19/00: | Drugs for skeletal disorders | |
A61P19/02: | . for joint disorders, e.g. arthritis, arthrosis | |
A61P19/04: | . for non-specific disorders of the connective tissue | |
A61P19/06: | . Antigout agents, e.g. antihyperuricemic or uricosuric agents | |
A61P19/08: | . for bone diseases, e.g. rachitism, Paget's disease | |
A61P19/10: | . . for osteoporosis | |
A61P21/00: | Drugs for disorders of the muscular or neuromuscular system | |
A61P21/02: | . Muscle relaxants, e.g. for tetanus or cramps | |
A61P21/04: | . for myasthenia gravis | |
A61P21/06: | . Anabolic agents | |
A61P23/00: | Anaesthetics | |
A61P23/02: | . Local anaesthetics | |
A61P25/00: | Drugs for disorders of the nervous system | |
A61P25/02: | . for peripheral neuropathies | |
A61P25/04: | . Centrally acting analgesics, e.g. opioids | |
A61P25/06: | . Antimigraine agents | |
A61P25/08: | . Antiepileptics; Anticonvulsants | |
A61P25/10: | . . for petit-mal | |
A61P25/12: | . . for grand-mal | |
A61P25/14: | . for treating abnormal movements, e.g. chorea, dyskinesia | |
A61P25/16: | . . Anti-Parkinson drugs | |
A61P25/18: | . Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia | |
A61P25/20: | . Hypnotics; Sedatives | |
A61P25/22: | . Anxiolytics | |
A61P25/24: | . Antidepressants | |
A61P25/26: | . Psychostimulants, e.g. nicotine, cocaine | |
A61P25/28: | . for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia | |
A61P25/30: | . for treating abuse or dependence | |
A61P25/32: | . . Alcohol-abuse | |
A61P25/34: | . . Tobacco-abuse | |
A61P25/36: | . . Opioid-abuse | |
A61P27/00: | Drugs for disorders of the senses | |
A61P27/02: | . Ophthalmic agents | |
A61P27/04: | . . Artificial tears; Irrigation solutions | |
A61P27/06: | . . Antiglaucoma agents or miotics | |
A61P27/08: | . . Mydriatics or cycloplegics | |
A61P27/10: | . . for accommodation disorders, e.g. myopia | |
A61P27/12: | . . for cataracts | |
A61P27/14: | . . Decongestants or antiallergics | |
A61P27/16: | . Otologicals | |
A61P29/00: | Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs) | |
A61P29/02: | . without antiinflammatory effect | |
A61P31/00: | Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics | |
A61P31/02: | . Local antiseptics | |
A61P31/04: | . Antibacterial agents | |
A61P31/06: | . . for tuberculosis | |
A61P31/08: | . . for leprosy | |
A61P31/10: | . Antimycotics | |
A61P31/12: | . Antivirals | |
A61P31/14: | . . for RNA viruses | |
A61P31/16: | . . . for influenza or rhinoviruses | |
A61P31/18: | . . . for HIV | |
A61P31/20: | . . for DNA viruses | |
A61P31/22: | . . . for herpes viruses | |
A61P33/00: | Antiparasitic agents | |
A61P33/02: | . Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis | |
A61P33/04: | . . Amoebicides | |
A61P33/06: | . . Antimalarials | |
A61P33/08: | . . for Pneumocystis carinii | |
A61P33/10: | . Anthelmintics | |
A61P33/12: | . . Schistosomicides | |
A61P33/14: | . Ectoparasiticides, e.g. scabicides | |
A61P35/00: | Antineoplastic agents | |
A61P35/02: | . specific for leukemia | |
A61P35/04: | . specific for metastasis | |
A61P37/00: | Drugs for immunological or allergic disorders | |
A61P37/02: | . Immunomodulators | |
A61P37/04: | . . Immunostimulants | |
A61P37/06: | . . Immunosuppressants, e.g. drugs for graft rejection | |
A61P37/08: | . Antiallergic agents | |
A61P39/00: | General protective or antinoxious agents | |
A61P39/02: | . Antidotes | |
A61P39/04: | . Chelating agents | |
A61P39/06: | . Free radical scavengers or antioxidants | |
A61P41/00: | Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution | |
A61P43/00: | Drugs for specific purposes, not provided for in groups | |